NGS Panel "LUNG 1" : EGFR-BRAF-MET-KRAS
Back to the listEurofins Biomnis code
POUM1
Synonyms
- Companion test
- NGS
- oncology
- Solid tumor
- Targeted therapy
Specialty
Genetics
Clinical significance
The NGS "LUNG1" panel associated with the FISH unitary test fulfil the routine needs of clinicians for prescribing targeted therapies for locally advanced or metastatic NSCLC. In 2020, the EGFR (mutation), ALK (rearrangement), ROS1 (rearrangement), RET (rearrangement),BRAF (mutation), NTRK (rearrangement) and MET (mutation) status can be used to guide the selection of targeted therapy (TMA (temporary marketing authorization)). In addition, KRAS status is included in this panel.
Preanalytics
- Tumoral block included in paraffin or slides (6 slides 5µm) or DNA extract
- Ambient temperature
- A tube specifically for this analysis : No
Further information
Use the specific request form B9-INTGB: Oncology-Solid tumors
The use of the S25UK transport bag is Mandatory.
Attach the anatomopathological report
Specific equipment available
- S25 : Envelope Genetics and Molecular Oncology
Documents to download
Methodology
Targeted sequencing of cancer genes (NGS) : -Library : AmpliSeq Library PLUS for Illumina Custom Panel V1 - Amplicon-based targeted library preparation method -NGS Platform : MiSeq Illumina - Flowcell : microV2 (2x150pb) - Paired-end reads -Analysis software : Miseq control Software version 2.6.2.1 /SeqOne Platform v1.2 - CE Pipeline version : SomaVar v1.4 CE -Limit of detection : 5% -Minimum depth accepted : 500x -Human genome version : Hg19
Turnaround time
10 business days
Biomnis Lyon